Vanguard Group Inc Krystal Biotech, Inc. Transaction History

Vanguard Group Inc

$5.57 Trillion
Q4 2024

A detailed history of Vanguard Group Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,878,451 shares of KRYS stock, worth $526 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,878,451

Previous 2,849,744 1.01%

Holding current value

$526 Million

Previous $518 Million 12.98%

% of portfolio

0.01%

Previous 0.01%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$156.64 - $199.61 $4.5 Million - $5.73 Million	28,707 Added 1.01%	2,878,451 $451 Million
Q3 2024 Nov 13, 2024	SELL	$174.7 - $213.66 $3.39 Million - $4.14 Million	-19,392 Reduced 0.68%	2,849,744 $518 Million
Q2 2024 Aug 13, 2024	BUY	$153.12 - $183.64 $66.8 Million - $80.1 Million	436,357 Added 17.94%	2,869,136 $527 Million
Q1 2024 May 10, 2024	SELL	$108.01 - $179.35 $323,489 - $537,153	-2,995 Reduced 0.12%	2,432,779 $433 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $3.42 Million - $4.57 Million	35,632 Added 1.48%	2,435,774 $302 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $75.3 Million - $90.4 Million	693,852 Added 40.66%	2,400,142 $278 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $39.6 Million - $65.7 Million	504,060 Added 41.93%	1,706,290 $200 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $1.02 Million - $1.19 Million	14,120 Added 1.19%	1,202,230 $96.3 Million
Q4 2022 Feb 10, 2023	BUY	$63.14 - $79.9 $5.81 Million - $7.35 Million	91,978 Added 8.39%	1,188,110 $94.1 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $1.74 Million - $2.21 Million	26,844 Added 2.51%	1,096,132 $76.4 Million
Q2 2022 Aug 12, 2022	BUY	$48.93 - $73.47 $873,057 - $1.31 Million	17,843 Added 1.7%	1,069,288 $70.2 Million
Q1 2022 May 13, 2022	BUY	$51.99 - $72.11 $1.45 Million - $2.01 Million	27,835 Added 2.72%	1,051,445 $70 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $5.37 Million - $11.9 Million	134,952 Added 15.19%	1,023,610 $71.6 Million
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $2.2 Million - $3.04 Million	42,303 Added 5.0%	888,658 $46.4 Million
Q2 2021 Aug 13, 2021	BUY	$62.14 - $81.82 $52.6 Million - $69.2 Million	846,355 New	846,355 $57.6 Million

Others Institutions Holding KRYS

# of Institutions

299

Shares Held

24.3M

Call Options Held

388K

Put Options Held

233K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.69B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Krystal Biotech, Inc. Transaction History